BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35580327)

  • 21. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.
    Rutherford SC; Abramson JS; Bartlett NL; Barta SK; Khan N; Joyce R; Maddocks K; Ali-Shaw T; Senese S; Yuan Y; Westin J; Leonard JP
    Lancet Haematol; 2021 Nov; 8(11):e818-e827. PubMed ID: 34634256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial.
    Ladetto M; Cortelazzo S; Ferrero S; Evangelista A; Mian M; Tavarozzi R; Zanni M; Cavallo F; Di Rocco A; Stefoni V; Pagani C; Re A; Chiappella A; Balzarotti M; Zilioli VR; Gomes da Silva M; Arcaini L; Molinari AL; Ballerini F; Ferreri AJM; Puccini B; Benedetti F; Stefani PM; Narni F; Casaroli I; Stelitano C; Ciccone G; Vitolo U; Martelli M
    Lancet Haematol; 2021 Jan; 8(1):e34-e44. PubMed ID: 33357480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%.
    Mohamedbhai SG; Sibson K; Marafioti T; Kayani I; Lowry L; Goldstone AH; Linch DC; Ardeshna KM
    Br J Haematol; 2011 Jan; 152(2):175-81. PubMed ID: 21092025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas.
    Kujawski LA; Longo WL; Williams EC; Turman NJ; Brandt N; Mosher DF; Eickhoff JC; Kahl BS
    Cancer Invest; 2007 Mar; 25(2):87-93. PubMed ID: 17453819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma.
    Corazzelli G; Frigeri F; Russo F; Frairia C; Arcamone M; Esposito G; De Chiara A; Morelli E; Capobianco G; Becchimanzi C; Volzone F; Saggese M; Marcacci G; De Filippi R; Vitolo U; Pinto A
    Br J Haematol; 2012 Jan; 156(2):234-44. PubMed ID: 22098541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
    Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
    Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.
    Ogura M; Yamamoto K; Morishima Y; Wakabayashi M; Tobinai K; Ando K; Uike N; Kurosawa M; Gomyo H; Taniwaki M; Nosaka K; Tsukamoto N; Shimoyama T; Fukuhara N; Yakushijin Y; Ohnishi K; Miyazaki K; Sawada K; Takayama N; Hanamura I; Nagai H; Kobayashi H; Usuki K; Kobayashi N; Ohyashiki K; Utsumi T; Kumagai K; Maruyama D; Ohmachi K; Matsuno Y; Nakamura S; Hotta T; Tsukasaki K;
    Cancer Sci; 2018 Sep; 109(9):2830-2840. PubMed ID: 29957865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma.
    Chen AI; Leonard JT; Okada CY; Gay ND; Chansky K; Fan G; Dunlap JB; Raess PW; Braziel RM; Stentz A; Maziarz RT
    Leuk Lymphoma; 2018 Aug; 59(8):1884-1889. PubMed ID: 29199519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation.
    Sun H; Savage KJ; Karsan A; Slack GW; Gascoyne RD; Toze CL; Sehn LH; Abou Mourad Y; Barnett MJ; Broady RC; Connors JM; Forrest DL; Gerrie AS; Hogge DE; Narayanan S; Nevill TJ; Nantel SH; Power MM; Sutherland HJ; Villa D; Shepherd JD; Song KW
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):341-8. PubMed ID: 25656914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab/bendamustine/cytarabine for transplant-eligible patients with mantle cell lymphoma: A retrospective study.
    Shimizu Y; Kaji D; Watanabe O; Yamaguchi K; Kageyama K; Taya Y; Nishida A; Ishiwata K; Takagi S; Yamamoto H; Mori YA; Wake A; Uchida N; Taniguchi S; Yamamoto G
    Cancer Med; 2023 Jun; 12(11):12548-12552. PubMed ID: 37199050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
    Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
    Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
    Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A
    Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
    Doorduijn JK; Zijlstra JM; Lugtenburg PJ; Kersten MJ; Böhmer LH; Minnema MC; MacKenzie MA; van Marwijk Kooij R; de Jongh E; Snijders TJF; de Weerdt O; van Gelder M; Hoogendoorn M; Leys RBL; Kibbelaar RE; de Jong D; Chitu DA; Van't Veer MB; Kluin-Nelemans HC
    Br J Haematol; 2020 Aug; 190(3):385-393. PubMed ID: 32150297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
    Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia.
    Kasamon YL; Brodsky RA; Borowitz MJ; Ambinder RF; Crilley PA; Cho SY; Tsai HL; Smith BD; Gladstone DE; Carraway HE; Huff CA; Matsui WH; Bolaños-Meade J; Jones RJ; Swinnen LJ
    Leuk Lymphoma; 2013 Mar; 54(3):483-90. PubMed ID: 22835045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
    Hermine O; Hoster E; Walewski J; Bosly A; Stilgenbauer S; Thieblemont C; Szymczyk M; Bouabdallah R; Kneba M; Hallek M; Salles G; Feugier P; Ribrag V; Birkmann J; Forstpointner R; Haioun C; Hänel M; Casasnovas RO; Finke J; Peter N; Bouabdallah K; Sebban C; Fischer T; Dührsen U; Metzner B; Maschmeyer G; Kanz L; Schmidt C; Delarue R; Brousse N; Klapper W; Macintyre E; Delfau-Larue MH; Pott C; Hiddemann W; Unterhalt M; Dreyling M;
    Lancet; 2016 Aug; 388(10044):565-75. PubMed ID: 27313086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
    Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
    Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.
    Sparano JA; Lee JY; Kaplan LD; Levine AM; Ramos JC; Ambinder RF; Wachsman W; Aboulafia D; Noy A; Henry DH; Von Roenn J; Dezube BJ; Remick SC; Shah MH; Leichman L; Ratner L; Cesarman E; Chadburn A; Mitsuyasu R;
    Blood; 2010 Apr; 115(15):3008-16. PubMed ID: 20023215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.